Spyre Therapeutics raises $463.5M in public offering to fund Phase 3 readiness

Filed April 16, 2026 · Period ending April 14, 2026 · ~1 min read

Key Changes

• high

  Completed public offering of 7.475 million shares at $62/share, raising $463.5M gross proceeds before fees. Underwriters exercised full overallotment option.

  Item 8.01 view on EDGAR →
• high

  Proceeds will fund inflammatory bowel disease and rheumatic disease programs, including clinical trials, manufacturing, and Phase 3 readiness for antibody programs.

  Item 8.01 view on EDGAR →
• high

  Offering represents approximately 7.5 million new shares at $62, diluting existing shareholders but extending clinical development runway significantly.

  Item 8.01 view on EDGAR →